MacroGenics VP Eric Blasius Risser Unloads 8,316 Shares (MGNX)
MacroGenics (NASDAQ:MGNX) VP Eric Blasius Risser sold 8,316 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $20.89, for a total transaction of $173,721.24. Following the transaction, the vice president now directly owns 5,000 shares of the company’s stock, valued at approximately $104,450. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
MacroGenics (NASDAQ:MGNX) traded down 2.43% on Tuesday, hitting $20.84. 183,471 shares of the company’s stock traded hands. MacroGenics has a 52-week low of $17.96 and a 52-week high of $41.00. The stock has a 50-day moving average of $20.38 and a 200-day moving average of $24.15. The company’s market cap is $578.1 million.
MacroGenics (NASDAQ:MGNX) last announced its earnings results on Tuesday, August 5th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.15. On average, analysts predict that MacroGenics will post $-1.39 earnings per share for the current fiscal year.
A number of research firms have recently commented on MGNX. Analysts at Oppenheimer initiated coverage on shares of MacroGenics in a research note on Thursday, July 10th. They set an “outperform” rating and a $48.00 price target on the stock. Separately, analysts at Roth Capital raised their price target on shares of MacroGenics from $28.00 to $30.00 in a research note on Thursday, June 19th. Finally, analysts at Roth Capital initiated coverage on shares of MacroGenics in a research note on Monday, June 9th. They set a “buy” rating and a $28.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, MacroGenics has a consensus rating of “Buy” and a consensus target price of $50.50.
MacroGenics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.